Purdue's promotion of OxyContin to physicians

Purdue's promotion of OxyContin to physicians turned a claim of low addiction risk into a national sales message, delivered through targeted visits, branded materials, free starter prescriptions, and resort conferences. Its significance lay not only in the claims made for the drug, but in the way those claims aligned with new medical standards that elevated pain assessment and treatment while leaving the meaning of adequate relief unsettled. The campaign reached beyond cancer care into ordinary medical practice, including rural towns where economic distress and disability were already widespread.

Claims and a changing standard of care

Purdue presented OxyContin as safe, reliable, and appropriate for a wide range of chronic pain. David Haddox, the pain specialist who became the company's principal advocate for the drug, promoted an addiction-risk estimate of less than one percent. Purdue's training materials described doctor-caused addiction as exceptionally rare. The reassurance was directed at physicians and dentists throughout the country, and its practical implication was expansive: OxyContin could be prescribed not only to people with advanced cancer, but also for moderate back injuries, wisdom-tooth surgery, bronchitis, and temporomandibular joint disorder.

The timing helped the message travel. OxyContin was introduced in 1996, as doctors, hospitals, and accreditation bodies were adopting pain as the fifth vital sign, alongside blood pressure, heart rate, respiratory rate, and temperature. In 1999, the Joint Commission on Accreditation of Healthcare Organizations approved mandatory standards for pain assessment and treatment. At the same time, health care was increasingly organized around patient-consumer satisfaction surveys. Hospitals and doctors competed for high scores, with reimbursement at stake, creating pressure to treat pain more aggressively.

Yet the campaign and the new standards operated within a basic uncertainty: what counted as adequate pain relief? Pain scales made it possible to standardize assessment, but the number recorded depended on a patient's subjective report. A transition in labor and a stubbed toe could both be rated at the maximum, depending on individual tolerance. Experts later acknowledged that the apparent objectivity of the scale did not make pain objectively measurable in this way. The book notes that reliance on these scales did not correlate with improved patient outcomes, while it was associated with increased opioid prescribing and abuse.

A national sales apparatus

Purdue's marketing strategy made the new institutional emphasis on pain a commercial opportunity. In its planning, the company described an opening to be regarded as a leader in helping hospitals meet accreditation requirements. It proposed pain-assessment and pain-management materials for hospital settings, while budgeting for hundreds of thousands of dollars in branded scroll pens, resource binders, wall charts, and clipboards. The materials linked OxyContin to the work of measuring and managing pain, placing the brand in the everyday surroundings of clinicians.

The wider promotional climate was also changing. After the U.S. Food and Drug Administration loosened rules for pharmaceutical advertising, spending on drug advertising rose from $360 million in 1995 to $1.3 billion in 1998. With few industry or federal guidelines governing prescription-drug promotion, companies increasingly used free items and messages that presented medication as a response to a broad range of problems. Purdue's campaign belonged to this environment, but it developed a particularly organized approach to reaching physicians likely to prescribe pain medication.

Purdue used data from IMS Health to identify doctors who prescribed large amounts of competing drugs such as Percocet and Vicodin. Sales representatives then pitched OxyContin's potency and longer-lasting action to those physicians. A doctor's prescribing decile served as an estimate of that doctor's potential: the higher the decile, the more visits the physician could expect. Representatives brought branded reminders, including OxyContin clocks for examination rooms. Purdue expected its expanding sales force to make more than a million annual calls on doctors in hospitals and offices, targeting high prescribers as well as family physicians and promoting the drug for noncancer pain, including low-back pain, osteoarthritis, and injuries.

Rural targeting and escalating incentives

The drug had particular early success in rural, small-town America. Purdue representatives worked in communities including Big Stone Gap, Lebanon, and St. Charles, Virginia, where per-capita rates of displaced workers and work-related disability claims were high. The setting mattered to the campaign's reach: OxyContin was being pitched in places where pain and economic hardship were already part of many residents' lives. Representatives travelled winding roads in company-rented Ford Explorers, while branded clocks and other promotional objects extended the sales message into examination rooms.

The company's targeting increasingly favored family medicine. Five years before 2000, cancer doctors had been the leading prescribers of long-acting opioids; by 2000, family doctors were the largest single group prescribing OxyContin. Representatives' bonuses could reach $70,000 a year, with the amount tied to the milligrams physicians prescribed. The financial stakes also grew at the corporate level: sales-representative bonuses rose from $1 million in 1996, the year OxyContin entered the market, to $40 million in 2001. These figures show an incentive system in which physician prescribing volume was not incidental to promotion but central to how sales success was rewarded.

Purdue supplemented office visits with free starter prescriptions redeemable for a thirty-day supply. It also held more than forty national pain-management and speaker-training conferences during OxyContin's first five years. Doctors, nurses, and pharmacists—more than five thousand in all—attended all-expenses-paid gatherings at resorts from Boca Raton to Scottsdale. The program made promotional contact more than a passing sales pitch: it combined repeated visits, free samples, training events, and an account of pain care in which wider opioid use could appear medically responsible.

Assurances, consequences, and the treatment gap

The promotion's confidence contrasts with the uncertainty voiced by clinicians who later reconsidered the prescribing practices of the period. The head of emergency medicine at Carilion Clinic recalled that physicians had been urged to make pain a much higher priority, and that opioid prescribing rose without a sufficient understanding of its consequences. He also recalled believing that a patient could not become dependent on a two-week supply, a belief he later recognized as wrong. The contrast does not by itself establish that every prescription followed directly from Purdue's marketing; it does show how promotional assurances could reinforce a broader change in clinical habits whose risks were not yet well understood.

The book's later accounts of treatment make the distance between promotion and care visible. Jesse Bolstridge entered a Jacksonville rehabilitation program in January 2013, with detox and counseling, and briefly took buprenorphine before being tapered off after three weeks. The treatment left his mother with a $25,000 debt, despite insurance coverage. For Tess Henry, finding care during pregnancy meant reaching one of the few Virginia facilities that accepted patients receiving medication-assisted treatment; private insurance covered most of a $20,000 bill, while her father paid the $6,500 deductible from her college savings. These individual circumstances do not reduce to the sales campaign, but they show that broad pharmaceutical promotion did not ensure sustained, affordable access to addiction treatment.

By 2017, volunteers with Roanoke's Hope Initiative were using a five-page spreadsheet listing thirty-six rehabilitation and aftercare providers, matching possible placements to patients' finances and available beds. Some volunteers also helped arrange medication-assisted treatment, though disagreement persisted over treating addiction with medication. Access remained constrained by expense, waiting lists, and limits on the number of patients that certified prescribers could treat. In the same period, Warren Bickel received a grant to test ways of connecting overdose patients directly from emergency care to outpatient buprenorphine. The contrast gives the promotion its lasting significance in the book: a highly resourced effort had helped expand the place of opioids in pain care, while later efforts to connect people with evidence-based treatment had to work through fragmented systems and scarce capacity.